

GSK delivers strong 2023 performance and upgrades growth outlooks

“GSK delivered excellent performance in 2023, with clear highlights being the exceptional launch of Arexvy and continued progress in our pipeline. We are now planning for at least 12 major launches from 2025, with new Vaccines and Specialty Medicines for infectious diseases, HIV, respiratory and oncology. As a result of this progress and momentum, we expect to deliver another year of meaningful sales and earnings growth in 2024, and we are upgrading our growth outlooks for 2026 and 2031. We remain focused on delivering this potential - and more - to prevent and change the course of disease for millions of people.”

Emma Walmsley
Chief Executive Officer, GSK



Vaccines
£9.9bn
+25%, +24%
including and excluding COVID-19 solutions

Specialty Medicines
£10.2bn
-8%, +15%
including and excluding COVID-19 solutions, with HIV +13%

General Medicines
£10.2bn
+5%

Adjusted operating profit
£8.8bn
+12%, +16% including and excluding COVID-19 solutions

Total EPS
121.6p +16%

Adjusted EPS
155.1p
+16%, +22% including and excluding COVID-19 solutions

Increased Dividend
Q4 FY
16p 58p

71
vaccines and specialty medicines in pipeline

18
pipeline assets in phase III / registration

Journalists/media see press release on www.gsk.com for full details on FY 2023.
Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 20-22 and 54-55 of the press release.
Product group sales may not add to total sales due to rounding.
References to growth are at constant exchange rates (CER) and for continuing operations unless stated otherwise.